Century Therapeutics (IPSC) Cash & Equivalents (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Cash & Equivalents data on file, last reported at $51.0 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $51.0 million, down 71.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $51.0 million (down 71.66% YoY), and the FY2025 annual result was $113.3 million, up 93.86% from the prior year.
• Cash & Equivalents retreated to $51.0 million in Q1 2026 per IPSC's latest filing, from $113.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $180.1 million in Q1 2025 and troughed at $41.5 million in Q2 2024.
• A 5-year average of $83.3 million and a median of $64.4 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2025 and 2026: Cash & Equivalents surged 284.75% in 2025, then plunged 71.66% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $84.3 million in 2022, then slumped by 43.84% to $47.3 million in 2023, then grew by 23.49% to $58.4 million in 2024, then soared by 93.86% to $113.3 million in 2025, then sank by 54.94% to $51.0 million in 2026.
• Business Quant data shows IPSC's Cash & Equivalents at $51.0 million in Q1 2026, $113.3 million in Q4 2025, and $127.0 million in Q3 2025.